Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | Cancelled | |||
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
| BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
| Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
| VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn |
Last Updated : April 30, 2024